• The biotech company’s sales in the United States grew by 27 three months of the year compared to Q1 2024
• The cosmetics market recognizes the company’s innovations worldwide

Barcelona, May 8, 2025.- Vytrus Biotech, a company specializing in active ingredients derived from plant biotechnology for the cosmetics industry, has obtained a new patent in the United States to protect healing applications of innovations in its portfolio.

The United States Patent and Trademark Office (USPTO) has granted Vytrus a patent for skin rejuvenation and healing care. The patent called “CELL-FREE PLANT CELL CULTURE SUSPENSION SUPERNATANT WITH RE-YOUTH ACTIVITY AND/OR WOUND HEALING ACTIVITY OVER SKIN CELLS” is valid until March 11, 2038.

This is the second recognition that the listed company has received from the intellectual property authorities of the United States, the world’s leading market for cosmetic ingredients with a volume of more than 4,000 million dollars in 2023. The patent covers several active ingredients from the company’s own pipeline (CLARIVINE™ and CENTELLA REVERSA),™ specifically for skin wound healing applications. These products are rich in plant peptides, as well as natural plant exosomes, molecules that are highly demanded by the dermocosmetic market globally for their multiple skin care benefits. vytrus.com

The United States is the company’s main market after Europe. Vytrus expects the patent grant to further boost its expansion in the country, supporting strong double-digit sales growth. Double-digit sales growth in Q1-2025 and recognition for innovation Vytrus achieved a global growth of +76percent in sales in the first 3 months of 2025 compared to the same period in 2024. All the geographical areas where Vytrus operates experienced strong growth. U.S. sales during the first quarter rose by 27percent year-over-year. The growth to March 2025 has boosted Vytrus’ year-on-year sales (sales in the last 12 months) which have reached €5.9 million for the first time in its history. Vytrus products incorporating Exosomic Peptides technology have partly driven sales growth in this first quarter. Among its products categories, anti-ageing, hair care and brightening solutions were the ones that performed best.

Vytrus has already sold its products in a total of 42 countries. This strong sales performance, combined with strict operational cost management, enabled the company to increase its EBITDA by 102percent compared to the same period in 2024, reaching €1.02 million. The cosmetics industry has recognized the company’s innovations. In April 2025, Vytrus launched its new proprietary product on the market, CLARIVINE,™ a 100percent natural biotechnological active ingredient based on vine stem cells. CLARIVINE™ introduces an innovative approach in cosmetics to promote skin longevity and a “glass skin” by mimicking the effects of intermittent fasting on skin cells. CLARIVINE™ has been recognized for its cosmetic innovation among more than 200 innovations with the Silver Best Ingredient Award from in-cosmetics Global 2025, the global trade fair for personal care ingredients held in Amsterdam last April. Two active ingredients in Vytrus containing natural plant exosomes (CENTELLA REVERSA™ and CAPILIA LONGA™) were also awarded at the BSB Innovation Awards 2025.